IRVING, Texas, June 19 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. today announced that its wholly-owned subsidiary Sabila Industrial in Liberia, Costa Rica has signed an extension of its existing contract with Servicios de Alcohol S.A. (SERCOHOL), a Costa Rican firm that has done business with Carrington for nearly fifteen years.
An adequate supply of medicinal grade alcohol is critical to the Sabila Industrial operations. Sabila produces all of Carrington’s raw materials: Hydrapol(TM), Manapol(R), Acemannan Hydrogel(TM), Acemannan Immunostimulant(TM) (raw material), and GelSite(R), the raw material used by Carrington’s wholly owned subsidiary DelSite in the nasal delivery of vaccines and therapeutics. New raw materials currently being developed will also use alcohol.
Mr. Jose Zuniga, vice president of Operations at Carrington, stated, “The extension of the current alcohol contract will allow us to plan, develop, and produce new raw materials needed by Carrington and DelSite, with essentially the same pricing and conditions as the current contract.”
SERCOHOL will continue to operate onsite facilities to recover and purify the alcohol used in the processing of Carrington’s raw materials. The contract will run through May 30, 2013.
About Carrington
Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally-occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. Carrington’s DelSite Biotechnologies subsidiary is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs. Carrington’s technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonlabs.com.
Certain statements in this release concerning Carrington may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company’s management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company’s filings with the Securities & Exchange Commission, including the Form 10-Q, filed May 15, 2007.
Carrington Laboratories, Inc.
CONTACT: Carlton E. Turner, Chief Executive Officer of CarringtonLaboratories, Inc., +1-972-518-1300
Web site: http://www.carringtonlabs.com/
